← Back to Screener
Rani Therapeutics Holdings, Inc. Class A Common Stock (RANI)
Price$0.97
Favorite Metrics
Price vs S&P 500 (26W)100.07%
Price vs S&P 500 (4W)-24.86%
Market Capitalization$118.30M
All Metrics
Book Value / Share (Quarterly)$0.27
P/TBV (Annual)2.73x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-15.64%
Cash Flow / Share (Quarterly)$-0.15
Price vs S&P 500 (YTD)-33.29%
Net Profit Margin (TTM)-1075.87%
EPS (TTM)$-0.59
10-Day Avg Trading Volume1.03M
EPS Excl Extra (TTM)$-0.59
Revenue Growth (5Y)10.75%
EPS (Annual)$-0.45
ROI (Annual)-89.89%
Net Profit Margin (5Y Avg)-2277.42%
Cash / Share (Quarterly)$0.41
Revenue Growth QoQ (YoY)42.12%
ROA (Last FY)-50.62%
EBITD / Share (TTM)$-0.57
ROE (5Y Avg)-392.26%
Operating Margin (TTM)-1293.57%
Cash Flow / Share (Annual)$-0.15
P/B Ratio3.58x
P/B Ratio (Quarterly)4.97x
Net Income / Employee (Annual)$-0
Net Interest Coverage (TTM)-18.84x
ROA (TTM)-108.12%
EPS Incl Extra (Annual)$-0.45
Current Ratio (Annual)4.21x
Quick Ratio (Quarterly)4.08x
3-Month Avg Trading Volume1.39M
52-Week Price Return-16.83%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.35
P/S Ratio (Annual)72.44x
Asset Turnover (Annual)0.03x
52-Week High$3.87
Operating Margin (5Y Avg)-3169.63%
EPS Excl Extra (Annual)$-0.45
CapEx CAGR (5Y)-40.70%
26-Week Price Return108.82%
Quick Ratio (Annual)4.08x
13-Week Price Return-31.69%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.21x
Enterprise Value$99.681
Revenue / Share Growth (5Y)3.90%
Asset Turnover (TTM)0.04x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-2507.65%
Cash / Share (Annual)$0.41
3-Month Return Std Dev86.66%
Net Income / Employee (TTM)$-0
ROE (Last FY)-89.89%
Net Interest Coverage (Annual)-15.61x
EPS Basic Excl Extra (Annual)$-0.45
Receivables Turnover (TTM)1.32x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.59
ROI (TTM)-31.22%
P/S Ratio (TTM)72.44x
Pretax Margin (5Y Avg)-3259.90%
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$0.75
Price vs S&P 500 (52W)-51.93%
Year-to-Date Return-29.16%
5-Day Price Return22.99%
EPS Normalized (Annual)$-0.45
ROA (5Y Avg)-45.25%
Net Profit Margin (Annual)-1817.09%
Month-to-Date Return30.12%
Cash Flow / Share (TTM)$-2.79
EBITD / Share (Annual)$-0.57
Operating Margin (Annual)-2381.26%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-69.41%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.59
P/TBV (Quarterly)5.73x
P/B Ratio (Annual)4.97x
Pretax Margin (TTM)-1335.70%
Book Value / Share (Annual)$0.27
Price vs S&P 500 (13W)-34.55%
Beta0.88x
Revenue / Share (TTM)$0.01
ROE (TTM)-31.22%
52-Week Low$0.39
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RANIRani Therapeutics Holdings, Inc. Class A Common Stock | 72.44x | — | — | — | $0.97 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Rani Therapeutics is a clinical-stage biotherapeutics company developing the RaniPill platform to deliver biologics such as antibodies, proteins, peptides, and oligonucleotides orally instead of by injection. The proprietary technology aims to provide patients and healthcare systems with a more convenient alternative to painful subcutaneous or intravenous injections. The company is also advancing RaniPill HC to enable delivery of liquid drug payloads with high bioavailability.